---
layout: default
title: Venetoclax
parent: 僅模型預測 (L5)
nav_order: 687
evidence_level: L5
indication_count: 10
---

# Venetoclax
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Venetoclax: From Chronic Lymphocytic Leukemia to Pregerminal-Center Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

## One-Sentence Summary

Venetoclax is a selective BCL-2 inhibitor originally used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The TxGNN model predicts it may also be effective specifically for **pregerminal-center (IGHV-unmutated) CLL/SLL**, a poorer-prognosis molecular subtype of the same disease, with a prediction score of **99.55%**, but currently only **1 tangential publication** and **no dedicated clinical trials** directly support this specific subtype-level claim.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) — local approved-indication text not available in this evidence pack |
| Predicted New Indication | Pregerminal-center chronic lymphocytic leukemia/small lymphocytic lymphoma |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L4 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on well-established public information, venetoclax is a first-in-class, orally bioavailable, selective BCL-2 (B-cell lymphoma 2) inhibitor. It restores the normal apoptotic pathway in malignant B cells that overexpress BCL-2 to evade programmed cell death, and it has proven efficacy in CLL/SLL and, in combination regimens, in acute myeloid leukemia.

The predicted new indication — "pregerminal-center CLL/SLL" — is not a distinct disease but a molecularly defined subtype of CLL/SLL, characterized by unmutated immunoglobulin heavy-chain variable region genes (U-IGHV) and a pre-germinal-center cell of origin, which is associated with a more aggressive clinical course than the mutated (M-CLL) subtype. Because venetoclax's mechanism (BCL-2 dependency blockade) is not IGHV-status-specific, it is mechanistically plausible that its activity extends across CLL/SLL molecular subtypes, including this one.

However, "mechanistic plausibility because it's the same underlying disease" is a weak form of repurposing evidence — this is closer to a label-granularity nuance than a genuine new indication. The only literature returned discusses B-cell receptor biology and CLL subtype classification in general, without directly studying venetoclax efficacy in this subgroup, and no clinical trials specific to this subtype were identified in the current search.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [35158929](https://pubmed.ncbi.nlm.nih.gov/35158929/) | 2022 | Review | Cancers | Reviews the biology of the tumor B-cell receptor (BCR) in CLL, including the distinction between pre-germinal-center (unmutated IGHV, poor prognosis) and post-germinal-center (mutated IGHV, good prognosis) subsets; provides mechanistic/classification background but does not directly study venetoclax in this subgroup. |

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (selective BCL-2 inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication is a molecular subtype of venetoclax's own original disease area rather than a genuinely new therapeutic area, yet it currently has zero dedicated clinical trials and only one indirectly relevant publication — evidence is too thin to support an active repurposing decision at this time.

**To proceed, the following is needed:**
- TFDA/NPRA package insert warnings and contraindications (currently a Blocking data gap; required before any S1 safety screening)
- Confirmed mechanism-of-action documentation (currently a High-severity data gap)
- Subtype-specific (IGHV-mutation-status-stratified) efficacy data for venetoclax in CLL/SLL, if it exists in registry or subgroup-analysis form
- Drug-drug interaction data (current DDI query returned no results)
- Consider prioritizing evaluation of other candidates in this same evidence pack with materially stronger evidence bases — e.g., follicular lymphoma (L2, multiple completed Phase 1/2 combination trials) and myeloid leukemia/Hodgkin lymphoma (50 trials and 20 publications each) — over this subtype-level candidate
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

